Lundbeck Announces CEO Succession Plan
Deborah Dunsire set to retire later this year.
Lundbeck, a biopharmaceutical company, has announced the upcoming retirement of CEO Deborah Dunsire. In her place, the board of directors have appointed Charl van Zyl to assume the position by October 1, 2023, at the latest. Currently, van Zyl works as EVP and head of neurology, responsible for corporate activities in Europe and international markets.
"On behalf of the Board of Directors, I would like to thank Deborah for her contributions over the past almost five years. Deborah has, together with the rest of the management team, done an excellent job in driving the strong commercial performance and changing and strengthening our R&D pipeline both through internal transformation and through some important acquisitions and licenses, creating a strong foundation for Lundbeck’s further growth and advancement,” says Lars Rasmussen, chairman of the board of directors. “We look forward to welcoming Charl as new President & CEO. His vast experience from the pharmaceutical industry and the CNS field combined with a strong patient focus and extensive market understanding and commercial execution track record from both listed companies and private equity makes him an excellent fit for Lundbeck.”
Reference: The Board of Directors initiates CEO succession. Cision. June 26, 2023. Accessed June 27, 2023. https://news.cision.com/h--lundbeck-a-s/r/the-board-of-directors-initiates-ceo-succession,c3793868
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
